|本期目录/Table of Contents|

[1]奚 昊,侯 健,袁振刚,等.VTD方案治疗复发难治性多发性骨髓瘤36例[J].医学研究与战创伤救治(原医学研究生学报),2010,12(01):36-38.
　XI Hao,HOU Jian,YUAN Zhen-gang,et al.Efficacy of VTD regimen on 36 patients with relapsed and refractory multiple myeloma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(01):36-38.
点击复制

VTD方案治疗复发难治性多发性骨髓瘤36例()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第12卷
期数:
2010年01期
页码:
36-38
栏目:
出版日期:
2010-01-20

文章信息/Info

Title:
Efficacy of VTD regimen on 36 patients with relapsed and refractory multiple myeloma
文章编号:
1672-271X(2010)01-0036-03
作者:
奚 昊; 侯 健; 袁振刚; 傅卫军; 张春阳
200003上海，第二军医大学长征医院血液内科
Author(s):
XI Hao;  HOU Jian;  YUAN Zhen-gang;  FU Wei-jun; ZHANG Chun-yang.
Department of Hematology, Changzheng Hospital, the Second Military Medical University，Shanghai 200003，China
关键词:
多发性骨髓瘤; 硼替佐米; 沙利度胺; 地塞米松; 联合治疗
Keywords:
multiple myeloma;  bortezomib;  thalidomide;  dexamethasone;  combination regimen
分类号:
R733.3
DOI:
-
文献标志码:
A
摘要:
目的 观察硼替佐米联合沙利度胺、地塞米松(VTD)方案治疗多发性骨髓瘤的疗效和不良反应。方法 采用VTD方案治疗复发难治性多发性骨髓瘤患者36例。结果 36例患者平均完成3.8个疗程，总有效率为80.6%。主要不良反应为血小板减少、乏力、周围神经病变等。结论 VTD方案治疗复发难治性多发性骨髓瘤的疗效好，且不良反应少、易耐受。
Abstract:
Objective To investgate the clinical efficacy and side effects on Velcade in combines with thalidomide and dexamethasone. Methods Velcade combines with Thalidomide and Dexamethasone was given to 36 patients with relapsed and refractory MM．Results 36 patients were treated with a mean 3.8 cycles. The OR rate was 80.6%. The main side effects were thrombocytopenia, fatigue, peripheral neuropathy, constipation, infection, etc．Conclusion The combination of Velcade, thalidomide with dexamethasone was effective in treatment of patients with relapsed and refractory MM，and could be well tolerated．

参考文献/References:

[1] Rajkumar SV，Kyle RA. Multiple myeloma:diagnosis and treatment[J].Mayo Clin Proc，2005，80(10):1371-1382.
[2] Pineda-Roman M，Zangari M，van Rhee F，et a1. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma[J].Leukemia，2008，22(7):1419-1427.
[3] Durie BGM，Harousseau JL，Miguel JS，et a1. International uniform response criteria for multiple myeloma[J].Leukemia，2006，20(9):1467-1473.
[4] Singhal S，Mehta J，Desikan R，et a1. Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med，1999，341(21):l565-1571．
[5] Palumbo A，Giaccone L，Bertola A，et a1. Low dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma[J].Haematologica，2001，86(4):399-403.
[6] Jagannath S，Durie BG，Wolf J，et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol，2005，129(6):776-783.
[7] Pineda-Roman M，Zangari M，van Rhee F，et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma[J].Leukemia，2008，22(7):1419-1427.
[8] Wang M，Giralt S，Delasalle K，et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma[J]. Hematology，2007，12(3):235-239.
[9] Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J]. Blood，2008，112(5):1593-1599.

相似文献/References:

[1]张玲玲,王 勇,邵先安.多发性骨髓瘤误诊1例[J].医学研究与战创伤救治(原医学研究生学报),2008,10(03):177.
[2]屈敏.复发多发性骨髓瘤患者预后因素分析[J].医学研究与战创伤救治(原医学研究生学报),2017,19(04):376.[doi:10.3969/j.issn.1672-271X.2017.04.011]
　QU Min.Analysis of prognostic factors of patients with multiple myeloma recrudescence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(01):376.[doi:10.3969/j.issn.1672-271X.2017.04.011]
[3]杜晓凤,庄莉,张曼,等.硼替佐米联合地塞米松治疗原发性系统性淀粉样变性的不良反应观察和护理对策[J].医学研究与战创伤救治(原医学研究生学报),2017,19(05):527.[doi:10.3969/j.issn.1672-271X.2017.05.021]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2010-01-20